ArticleSmall GTPases2018
PAK1 regulates inhibitory synaptic function via a novel mechanism mediated by endocannabinoids.
Article in Small GTPases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 9 citations in OpenAlex.
- PAK1 (p21-Activated Kinase 1) and Its Role in Neurodevelopmental Disorders-New Case Report and a Comprehensive Review.International journal of molecular sciences · 2025Review
- Review
- Neurodevelopmental disorders, like cancer, are connected to impaired chromatin remodelers, PI3K/mTOR, and PAK1-regulated MAPK.Biophysical reviews · 2023Review
- The molecular basis of p21-activated kinase-associated neurodevelopmental disorders: From genotype to phenotype.Frontiers in neuroscience · 2023Review
- Group I PAKs in myelin formation and repair of the central nervous system: what, when, and how.Biological reviews of the Cambridge Philosophical Society · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
The Rho family small GTPases and their effectors, including PAKs, are extensively studied in the context of the actin cytoskeleton, excitatory synaptic function, spine morphology and memory formation. However, their roles in inhibitory synaptic function remain poorly understood. We have recently shown that PAK1 is a potent regulator of GABAergic synaptic transmission. Thus, disruption of PAK1 leads to significant impairments in inhibitory postsynaptic currents which are manifested as reduced GABA presynaptic releases. Interestingly, this effect of PAK1 is distinct from its previously known role in spines and excitatory synaptic transmission in that it is independent of postsynaptic actin, but requires retrograde messengers produced and released from the postsynaptic neurons to suppress presynaptic GABA releases. We have further identified eCBs as the retrograde messengers and shown that PAK1 regulates the eCB signaling via restricting the tissue level of AEA by promoting synaptic expression of COX-2, a key enzyme to oxidize AEA. These results have established a novel pathway whereby PAK1, and by extension Rho proteins, regulates cellular processes, synaptic function and behaviors and have important implications in understanding and treating various diseases linked to PAKs and Rho signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.